#175 Above Health: The Allergy Clinic of the Future

What It Covers

Matt Truby pitches Above Health, an AI diagnostic platform combining telehealth, custom lab panels, and proprietary hardware devices to revolutionize allergy and asthma care, raising $450,000 from four investors at a $10 million valuation.

Key Questions Answered

• •Hardware cost innovation: Matt builds clinical-grade devices at unprecedented prices—a smart inhaler with GPS for $1,000 per prototype iteration and a diagnostic stethoscope for $9.99 manufacturing cost, compared to traditional costs of $500,000 and $88 respectively, enabling mass distribution.
• •Value-based care acceleration: Above Health targets value-based care contracts within two years instead of the typical five by combining telehealth with proprietary devices as differentiators, starting with underserved markets like Kern County with 700,000 people and zero allergists.
• •Precision diagnostics approach: The platform uses GPS-enabled inhalers to capture location, pollen, and air quality data within one square kilometer, then offers targeted lab testing for specific allergens like Cottonwood instead of expensive 50-allergen panels with 20% false positives.
• •Market entry strategy: Customer acquisition cost of $10 through free at-home allergy stickers promoted on parent forums, booking telehealth visits through October while building toward retail distribution and health system contracts, maintaining $3,000-4,000 monthly burn rate with just the founder full-time.